Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 11
Submit an article Journal homepage
399
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Triptolide, a Chinese Herbal Extract, Enhances Drug Sensitivity of Resistant Myeloid Leukemia Cell Lines Through Downregulation of HIF-1α and Nrf2

Feili Chen1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR ChinaView further author information
,
Yuejian Liu1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR ChinaView further author information
,
Shiyun Wang1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR ChinaView further author information
,
Xutao Guo1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR ChinaView further author information
,
Pengcheng Shi1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR ChinaView further author information
,
Weiguang Wang2 Research Institute in Healthcare Science, School of Applied Sciences, University of Wolverhampton, Wolverhampton, UKView further author information
&
Bing Xu1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1305-1317 | Published online: 09 Aug 2013

References

  • Damiani D , TiribelliM, RaspadoriD et al. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematol. Oncol. 25(1) , 38–43 (2007).
  • Graziose R , LilaMA, RaskinI. Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr. Drug Discov. Technol.7(1) , 2–12 (2010).
  • Liu Q . Triptolide and its expanding multiple pharmacological functions. Int. Immunopharmacol.11(3) , 377–383 (2011).
  • Meng HT , ZhuL, NiWM, YouLS, JinJ, QianWB. Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-κB activity and miR-16-1*. Acta Pharmacol. Sin.32(4) , 503–511 (2011).
  • Pigneux A , MahonFX, UhaldeM et al. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp. Hematol. 36(12) , 1648–1659 (2008).
  • Wang W , LiX, SunW et al. Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of decoy receptor 3 expression. J. Cancer Res. Clin. Oncol. 138(9) , 1597–1605 (2012).
  • Wu PP , LiuKC, HuangWW et al. Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. Oncol. Rep. 25(2) , 551–557 (2010).
  • Tengchaisri T , ChawengkirttikulR, RachaphaewN, ReutrakulV, SangsuwanR, SirisinhaS. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett.133(2) , 169–175 (1998).
  • Xu B , GuoX, MathewS et al. Triptolide simultaneously induces reactive oxygen species, inhibits NF-κB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett. 291(2) , 200–208 (2009).
  • Shamon LA , PezzutoJM, GravesJM et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett. 112(1) , 113–117 (1997).
  • Xiaowen H , YiS. Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation. Mol. Biol. Rep.39(9) , 8763–8770 (2012).
  • Zhu W , LiJ, WuS et al. Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas 41(7) , 1029–1038 (2012).
  • Huang X , YangM, JinJ. Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs. Leuk. Lymphoma53(6) , 1188–1195 (2012).
  • Sporn MB , LibyKT. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer12(8) , 564–571 (2012).
  • Higgins LG , KelleherMO, EgglestonIM, ItohK, YamamotoM, HayesJD. Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. Toxicol. Appl. Pharmacol.237(3) , 267–280 (2009).
  • Rushworth SA , ZaitsevaL, MurrayMY, ShahNM, BowlesKM, MacewanDJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance. Blood120(26) , 5188–5198 (2012).
  • Zhong Y , ZhangF, SunZ et al. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol. Carcinog. doi:10.1002/mc.21921 (2012) (Epub ahead of print).
  • Chowdhry S , ZhangY, McMahonM, SutherlandC, CuadradoA, HayesJD. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene doi:10.1038/onc.2012.388 (2012) (Epub ahead of print).
  • Marin-Hernandez A , Gallardo-PerezJC, RalphSJ, Rodriguez-EnriquezS, Moreno-SanchezR. HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev. Med. Chem.9(9) , 1084–1101 (2009).
  • Rankin EB , GiacciaAJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ.15(4) , 678–685 (2008).
  • Harris AL . Hypoxia – a key regulatory factor in tumour growth. Nat. Rev. Cancer2(1) , 38–47 (2002).
  • Matsunaga T , ImatakiO, ToriiE et al. Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk. Res. 36(6) , e122–e124 (2012).
  • Deeb G , VaughanMM, McInnisI et al. Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk. Res. 35(5) , 579–584 (2011).
  • Escherich G , ZimmermannM, Janka-SchaubG. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07–03. Pediatr. Blood Cancer60(2) , 254–257 (2012).
  • Lee HJ , ThompsonJE, WangES, WetzlerM. Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer117(8) , 1583–1594 (2011).
  • Baran Y , GurB, KayaP, UralAU, AvcuF, GunduzU. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology12(6) , 511–517 (2007).
  • Qi J , PengH, GuZL, LiangZQ, YangCZ. Establishment of an imatinib resistant cell line K562/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi25(6) , 337–341 (2004).
  • Chou TC , TalalayP. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul.22 , 27–55 (1984).
  • Tang X , WangH, FanL et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic. Biol. Med. 50(11) , 1599–1609 (2011).
  • Jung CW , JoJR, LeeSH et al. Anti-cancer properties of glucosamine-hydrochloride in YD-8 human oral cancer cells: induction of the caspase-dependent apoptosis and down-regulation of HIF-1α. Toxicol. In vitro26(1) , 42–50 (2012).
  • Ioannou M , PyrpasopoulouA, SimosG et al. Upregulation of VEGF expression is associated with accumulation of HIF-1α in the skin of naive scleroderma patients. Mod. Rheumatol. doi:10.1007/s10165-012-0787-6 (2012) (Epub ahead of print).
  • Oh YS , KimHY, SongIC et al. Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1α. Oncol. Rep. 28(6) , 2239–2246 (2012).
  • Zhou ZL , LuoZG, YuB et al. Increased accumulation of hypoxia-inducible factor-1α with reduced transcriptional activity mediates the antitumor effect of triptolide. Mol. Cancer 9(1) , 268 (2010).
  • Wilczynski J , DuechlerM, CzyzM. Targeting NF-αB and HIF-1 pathways for the treatment of cancer: part I. Arch. Immunol. Ther. Exp. (Warsz.)59(4) , 289–299 (2011).
  • Wilczynski J , DuechlerM, CzyzM. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II. Arch. Immunol. Ther. Exp. (Warsz.)59(4) , 301–307 (2011).
  • Zhao F , MancusoA, BuiTV et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming. Oncogene 29(20) , 2962–2972 (2010).
  • Zhong H , MabjeeshN, WillardM, SimonsJ. Nuclear expression of hypoxia-inducible factor 1α protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett.181(2) , 233–238 (2002).
  • Wang Y , LiuY, MalekSN, ZhengP. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell8(4) , 399–411 (2011).
  • Doublier S , BelisarioDC, PolimeniM et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 12 , 4 (2012).
  • Lang L , TangK, LiY, LiuX, WangC, ChenX. Identification of two small molecule inhibitors of hypoxia-inducible factor 1 with different cell-based screening model. Zhongguo Zhong Yao Za Zhi37(14) , 2151–2155 (2012).
  • Rushworth SA , BowlesKM, MacewanDJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res.71(5) , 1999–2009 (2011).
  • Tarumoto T , NagaiT, OhmineK et al. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp. Hematol. 32(4) , 375–381 (2004).
  • Nagai T , KikuchiS, OhmineK et al. Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. J. Cell Biochem. 104(2) , 680–691 (2008).
  • Ren D , VilleneuveNF, JiangT et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl Acad. Sci. USA 108(4) , 1433–1438 (2011).
  • Li J , JinJ, LiM et al. Role of Nrf2 in protection against triptolide-induced toxicity in rat kidney cells. Toxicol. Lett. 213(2) , 194–202 (2012).
  • Baird L , Dinkova-KostovaAT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol.85(4) , 241–272 (2011).
  • Chapple SJ , SiowRC, MannGE. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int. J. Biochem. Cell Biol.44(8) , 1315–1320 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.